3-[2-(1H-imidazol-1-yl)ethoxy]benzamine | 112677-70-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[2-(1H-imidazol-1-yl)ethoxy]benzamine
• 英文别名: 3-[2-(1H-Imidazol-1-yl)ethoxy]aniline；3-(2-imidazol-1-ylethoxy)aniline
• CAS: 112677-70-0
• 化学式: C₁₁H₁₃N₃O
• mdl: MFCD11652481
• 分子量: 203.244
• InChiKey: MSHCBMNAPXVHPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[2-(1H-imidazol-1-yl)ethoxy]benzamine 在 盐酸 、 sodium carbonate 作用下， 以 乙二醇甲醚 为溶剂， 反应 25.25h， 生成 (4-Furan-2-yl-pyrimidin-2-yl)-[3-(2-imidazol-1-yl-ethoxy)-phenyl]-amine
  参考文献：
  名称：

  Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

  摘要：

  The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.

  DOI：

  10.1021/jm00071a002
• 作为产物：
  描述：

  1-(2-溴乙氧基)-3-硝基苯 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[2-(1H-imidazol-1-yl)ethoxy]benzamine
  参考文献：
  名称：

  Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors

  摘要：

  We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.001

文献信息

• 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
  申请人：American Cyanamid Company

  公开号：US04788195A1

  公开（公告）日：1988-11-29

  This disclosure describes novel 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines having anti-asthmatic activity.

  这份披露描述了具有抗哮喘活性的新型4,5,6-取代-N-(取代苯基)-2-嘧啶胺。
• [EN] INHIBITORS OF TYROSINE KINASES<br/>[FR] INHIBITEURS DE TYROSINE KINASES
  申请人：NOVARTIS AG

  公开号：WO2004005281A1

  公开（公告）日：2004-01-15

  The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.

  该发明涉及式(I)的化合物，其中取代基R1、R2和R4的含义如所述并在发明说明中解释，以及制备这些化合物的方法，含有相同化合物的药物组合物，其可选择与一个或多个其他药用活性化合物结合使用，用于治疗对蛋白激酶活性抑制产生反应的疾病，尤其是肿瘤性疾病，特别是白血病，以及用于治疗此类疾病的方法。
• Inhibitors of tyrosine kinases
  申请人：NOVARTIS AG

  公开号：EP2100891A1

  公开（公告）日：2009-09-16

  The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

  本发明涉及公式的化合物，其中置换基R1、R2和R4的含义如本发明说明书中所述和解释的那样，以及制备这些化合物的过程，包含它们的制药组合物，其可选择与一个或多个其他药物活性化合物联合使用，用于治疗对蛋白激酶活性抑制有反应的疾病，尤其是肿瘤性疾病，特别是白血病，并且提供了一种治疗这种疾病的方法。
• INHIBITORS OF TYROSINE KINASES
  申请人：Breitenstein Werner

  公开号：US20090286821A1

  公开（公告）日：2009-11-19

  The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

  该发明涉及以下式子的化合物：其中取代基R1、R2和R4的含义如发明说明中所述和解释的那样，以及制备这些化合物的过程，包含这些化合物的药物组合物，与一种或多种其他药物活性化合物结合使用治疗对蛋白激酶活性抑制有反应的疾病，特别是肿瘤性疾病，特别是白血病，以及治疗这种疾病的方法。
• 4,5,6-Substituted-2-pyrimidinamines
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0233461A2

  公开（公告）日：1987-08-26

  This disclosure describes novel 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines having anti-asthmatic activity.

  本公开介绍了具有抗哮喘活性的新型 4,5,6-取代-N-（取代苯基）-2-嘧啶胺。